{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:26:29Z","timestamp":1781760389169,"version":"3.54.5"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Akathisia is an underestimated but disturbing extrapyramidal side effect of antidepressants, which could reduce treatment compliance in mood disorders. This study aimed to investigate the frequency and risk factors in patients treated with selective serotonin reuptake inhibitors\/serotonin and noradrenaline reuptake inhibitors (SSRI\/SNRI). In addition, we assessed the impact of akathisia on the quality of life (QoL). Patients were aged between 18 and 75 years, receiving an SSRI\/SNRI for 4\u20138 weeks, and were diagnosed with anxiety, depression, or obsessive-compulsive disorder. The Barnes Akathisia Rating Scale was used to assess the severity of the akathisia. QoL was evaluated using the Short Form 36 (SF-36) questionnaire. Akathisia was observed in 25% (50\/198) of patients. Smokers and younger patients were more frequent among patients with akathisia. Physical functioning, physical role, vitality, and mental health domains of the SF-36 were reduced in the presence of akathisia. In conclusion, our results suggest that akathisia is not a rare side effect of SSRI\/SNRI in patients with mood disorders, especially in smokers and younger patients. In addition, akathisia may reduce treatment compliance owing to a reduction in QoL. Further investigations are needed to confirm the risk factors, frequency, and consequences of treatment compliance for SSRI\/SNRI-induced akathisia in patients with mood disorders.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000797","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T11:00:10Z","timestamp":1728298810000},"page":"460-463","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of akathisia in patients receiving selective serotonin reuptake inhibitors\/serotonin and noradrenaline reuptake inhibitors"],"prefix":"10.1097","volume":"35","author":[{"given":"Ismail","family":"Akgoz","sequence":"first","affiliation":[{"name":"Department of Medical Pharmacology, Eskisehir State Authority, Eskisehir"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Akdeniz University Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgen","family":"Ozcelik","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Akdeniz University Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Donmez","sequence":"additional","affiliation":[{"name":"Department of Public Health, Akdeniz University Medical Faculty"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Eryilmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Akdeniz University Medical Faculty, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul","family":"Ozbey","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Akdeniz University Medical Faculty, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0006-3223(94)00158-Y","article-title":"Paroxetine and akathisia.","volume":"37","author":"Adler","year":"1995","journal-title":"Biol Psychiatry"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0010-440X(96)90572-6","article-title":"Akathisia: a review and case report following paroxetine treatment.","volume":"37","author":"Baldassano","year":"1996","journal-title":"Compr Psychiatry"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4274\/tnd.37043","article-title":"Reliability and validity of the Turkish version of the Barnes Akathisia Rating Scale.","volume":"23","author":"Bayram","year":"2017","journal-title":"Turkish J Neurol"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0924-9338(98)80029-1","article-title":"A case of paroxetine-induced akathisia and a review of SSRI-induced akathisia.","volume":"13","author":"Bonnet-Brilhault","year":"1998","journal-title":"Eur Psychiatry"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/106002809703101208","article-title":"Extrapyramidal reactions and the selective serotonin-reuptake inhibitors.","volume":"31","author":"Caley","year":"1997","journal-title":"Ann Pharmacother"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/YIC.0000000000000466","article-title":"Frequency, risk factors, and impacts on quality of life of the restless legs syndrome and side effects among antidepressant users in a tertiary hospital: an observational cross-sectional study.","volume":"38","author":"Cetin Erdem","year":"2023","journal-title":"Int Clin Psychopharmacol"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"bcr2012007713","DOI":"10.1136\/bcr-2012-007713","article-title":"Akathisia: a life-threatening side effect of a common medication.","volume":"2013","author":"Cheng","year":"2013","journal-title":"BMJ Case Rep"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40263-019-00625-3","article-title":"Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis.","volume":"33","author":"Demyttenaere","year":"2019","journal-title":"CNS Drugs"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/15622975.2017.1379609","article-title":"Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement.","volume":"19","author":"Dodd","year":"2018","journal-title":"World J Biol Psychiatry"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"56","DOI":"10.18773\/austprescr.2019.014","article-title":"Drug-induced movement disorders.","volume":"42","author":"Duma","year":"2019","journal-title":"Aust Prescr"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1345\/aph.17302","article-title":"Selective serotonin-reuptake inhibitor-induced movement disorders.","volume":"32","author":"Gerber","year":"1998","journal-title":"Ann Pharmacother"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4103\/0253-7613.144948","article-title":"Venlafaxine induced akathisia: a case report.","volume":"46","author":"Grover","year":"2014","journal-title":"Indian J Pharmacol"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0000000000000911","article-title":"Association of antidepressant use with drug-related extrapyramidal symptoms: a pharmacoepidemiological study.","volume":"38","author":"Guo","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpsychires.2015.04.020","article-title":"Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study.","volume":"66-67","author":"Han","year":"2015","journal-title":"J Psychiatr Res"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.325","article-title":"A critical review of akathisia, and its possible association with suicidal behaviour.","volume":"16","author":"Hansen","year":"2001","journal-title":"Hum Psychopharmacol"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028015594812","article-title":"Extrapyramidal reactions associated with serotonergic antidepressants.","volume":"49","author":"Hawthorne","year":"2015","journal-title":"Ann Pharmacother"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"17m","DOI":"10.4088\/JCP.17m11764","article-title":"Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial.","volume":"79","author":"Hsu","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2710.2007.00848.x","article-title":"Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.","volume":"32","author":"Kim","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10067-002-0653-6","article-title":"The reliability and validity of the Turkish version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO).","volume":"22","author":"Kocyigit","year":"2003","journal-title":"Clin Rheumatol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1331\/JAPhA.2009.08083","article-title":"Selective serotonin reuptake inhibitor-induced akathisia.","volume":"49","author":"Koliscak","year":"2009","journal-title":"J Am Pharm Assoc"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/pcn.12017","article-title":"Venlafaxine-related akathisia side-effects and management in a depressed patient.","volume":"67","author":"Lai","year":"2013","journal-title":"Psychiatry Clin Neurosci"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0278-5846(98)00036-0","article-title":"Extrapyramidal adverse effects associated with sertraline.","volume":"22","author":"Lambert","year":"1998","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/026988119801200212","article-title":"SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.","volume":"12","author":"Lane","year":"1998","journal-title":"J Psychopharmacol"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(15)00308-6","article-title":"Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.","volume":"386","author":"Lenze","year":"2015","journal-title":"Lancet"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4088\/JCP.v57n1002","article-title":"Movement disorders associated with the serotonin selective reuptake inhibitors.","volume":"57","author":"Leo","year":"1996","journal-title":"J Clin Psychiatry"},{"issue":"20 Suppl 1","key":"R27-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852915000838","article-title":"The clinical challenges of akathisia.","volume":"20","author":"Lohr","year":"2015","journal-title":"CNS Spectr"},{"key":"R28-20250614","first-page":"50","article-title":"Antidepressant-induced activation in children and adolescents: risk, recognition and management.","volume":"48","author":"Luft","year":"2018","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1017\/S1092852900008269","article-title":"Quality of life in geriatric patients with mood and anxiety disorders.","volume":"8","author":"Maddux","year":"2003","journal-title":"CNS Spectr"},{"key":"R30-20250614","first-page":"148","article-title":"Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports.","volume":"22","author":"Madhusoodanan","year":"2010","journal-title":"Ann Clin Psychiatry"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jama.2017.8036","article-title":"Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial.","volume":"318","author":"Mohamed","year":"2017","journal-title":"JAMA"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/0006-3223(96)84504-5","article-title":"A case of paroxetine-induced akathisia.","volume":"39","author":"Olivera","year":"1996","journal-title":"Biol Psychiatry"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/08039488.2016.1268203","article-title":"Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder.","volume":"71","author":"Ozbey","year":"2017","journal-title":"Nord J Psychiatry"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2147\/NDT.S199746","article-title":"Cognitive impairment in depression: recent advances and novel treatments.","volume":"15","author":"Perini","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12888-020-02711-z","article-title":"Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.","volume":"20","author":"Revet","year":"2020","journal-title":"BMC Psychiatry"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2014.03.017","article-title":"Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.","volume":"162","author":"Stewart","year":"2014","journal-title":"J Affect Disord"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0010-440X(75)90019-X","article-title":"The many faces of akathisia.","volume":"16","author":"Van Putten","year":"1975","journal-title":"Compr Psychiatry"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T20:04:03Z","timestamp":1749931443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000797","relation":{},"ISSN":["0955-8810","1473-5849"],"issn-type":[{"value":"0955-8810","type":"print"},{"value":"1473-5849","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}